Patent 7691603 was granted and assigned to Novo Nordisk on April, 2010 by the United States Patent and Trademark Office.
The invention includes methods and compositions for forming peptide conjugates intracellularly having a covalent linkage between a modifying group and a glycosylated or non-glycosylated peptide. The modifying group is conjugated to the peptide via a glycosyl linking group interposed between and covalently linked to both the peptide and the modifying group.